期刊
ONCOLOGIST
卷 14, 期 10, 页码 970-978出版社
ALPHAMED PRESS
DOI: 10.1634/theoncologist.2009-0175
关键词
Colorectal cancer meta-analysis; Clinical trial phase III; Pharmacogenetics
类别
资金
- NCCTG Biospecimen Resource), Sanofi-Aventis, and Pharmacia [CA25224, CA114740]
- NATIONAL CANCER INSTITUTE [U24CA114740, U10CA025224] Funding Source: NIH RePORTER
N9741 is a clinical trial in patients with metastatic colorectal cancer that was originally written in 1997 and completed patient accrual in 2004. One thousand seven hundred thirty-one patients were enrolled in the study. During the conduct of the trial, N9741 was repeatedly modified to adapt to toxicity findings, to add evaluation of oxaliplatin to what was originally a trial examining various schedules of irinotecan-based therapy, and to ask evolving questions. The trial led to a new U. S. Food and Drug Administration indication for 5-fluorouracil, leucovorin, and oxaliplatin as indicated for the treatment of previously untreated patients with metastatic colorectal cancer and helped to change the standard of care for the disease in the U. S. and worldwide. The data from the trial have been used to study multiple regimens, pharmacogenetics, and quality of life issues, to correlate plasma protein levels with outcomes, to inform trial methodology, and to perform economic analyses. To date nearly 30 papers and an even larger number of abstracts have been based upon data arising from the study. The history of the trial and the major findings are summarized in this review. The Oncologist 2009; 14: 970-978
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据